Roche's Ocrevus: A Rare First-Year Blockbuster
Ocrevus generated roughly $935m in 2017 after launching in April, exceeding recent drug launches and putting the multiple sclerosis therapy in company with early successes like Opdivo, Ibrance, Tecfidera and Eylea.
You may also be interested in...
The drug enters the increasingly competitive space of CD20-targeting therapies for multiple sclerosis, with two agents already approved.
The anti-CD20 monoclonal antibody was approved by the US FDA for relapsing multiple sclerosis, bringing a new treatment to the crowded therapeutic area – with the benefit of self-administration.
Roche completed 80 significant deals in 2019, neuroscience partnering head Tom Zioncheck said, many of which helped the company build its growing pipeline in neurological diseases.